Literature DB >> 26952026

Addressing the burden of epilepsy: Many unmet needs.

Ettore Beghi1.   

Abstract

Epilepsy is a heterogeneous clinical condition characterized by recurrent unprovoked seizures, their causes and complications. The incidence, prevalence and mortality of epilepsy vary with age, place and time contributing to a variable extent to the burden of the disease. Diagnostic misclassification may have strong impact on personal and societal reflections of the disease in light of its clinical manifestations and the need for chronic treatment. Epilepsy accounts for a significant proportion of the world's disease burden ranking fourth after tension-type headache, migraine and Alzheimer disease. Among neurological diseases, it accounts for the highest disability-adjusted life year rates both in men and in women. Although epilepsy is self-remitting in up to 50% of cases, variable long-term prognostic patterns can be identified based on the response to the available treatments. Epilepsy carries an overall increased risk of premature mortality with variable estimates across countries. Premature mortality predominates in patients aged less than 50 years, with epilepsies due to structural/metabolic conditions, with generalized tonic-clonic seizures, and seizures not remitting under treatment. Among deaths directly attributable to epilepsy or seizures, included are sudden unexpected death in epilepsy (SUDEP), status epilepticus, accidents, drowning, unintentional injuries, and suicide. Somatic and psychiatric disorders prevail in patients with epilepsy than in people without epilepsy. Asthma, migraine and cerebral tumors tend to occur more frequently in younger adults while cardiovascular disorders, stroke, dementia and meningioma predominate in the elderly. As being a fairly common clinical condition affecting all ages and requiring long-term (sometimes lifelong) treatment, epilepsy carries high health care costs for the society. Direct costs peak in the first year after diagnosis and then vary according to the severity of the disease, the response to treatment, and the presence of comorbidity. Although in several countries the costs of epilepsy are met by the national health systems, out-of-pocket costs may be a relevant fraction of the overall costs, especially in countries where the public management of health care is suboptimal or non-existent. Epilepsy strongly affects patients' independence, psychological health and emotional adjustment. Epilepsy impairs all aspects of health-related quality of life. Awareness and attitudes of the public about epilepsy may significantly affect the burden of the disease. All these factors add to the burden of the disease. However, many of the factors implicated in the onset of epilepsy, its course and treatment can be favorably addressed with appropriate strategic plans. More research is needed to investigate and manage the medical and psychosocial implications of epilepsy.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Burden; Comorbidity; Epilepsy; Incidence; Mortality; Prevalence; Prognosis

Mesh:

Year:  2016        PMID: 26952026     DOI: 10.1016/j.phrs.2016.03.003

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  24 in total

1.  One-year follow-up of a remotely delivered epilepsy self-management program in high-risk people with epilepsy.

Authors:  Martha Sajatovic; Kari Colon-Zimmermann; Mustafa Kahriman; Edna Fuentes-Casiano; Christopher Burant; Michelle E Aebi; Kristin A Cassidy; Samden Lhatoo; Douglas Einstadter; Peijun Chen
Journal:  Epilepsy Behav       Date:  2019-05-21       Impact factor: 2.937

Review 2.  Glial source of nitric oxide in epileptogenesis: A target for disease modification in epilepsy.

Authors:  Shaunik Sharma; Sreekanth Puttachary; Thimmasettappa Thippeswamy
Journal:  J Neurosci Res       Date:  2017-12-12       Impact factor: 4.164

Review 3.  Advances in Autoimmune Epilepsy Associated with Antibodies, Their Potential Pathogenic Molecular Mechanisms, and Current Recommended Immunotherapies.

Authors:  Zhiwei Fang; Yunqi Yang; Xuan Chen; Weiwang Zhang; Yangmei Xie; Yinghui Chen; Zhenguo Liu; Weien Yuan
Journal:  Front Immunol       Date:  2017-04-25       Impact factor: 7.561

4.  Affective symptoms and determinants of health-related quality of life in Mexican people with epilepsy.

Authors:  Carlos R Camara-Lemarroy; Mariana Hoyos; Beatriz E Ibarra-Yruegas; Marco A Díaz-Torres; Rolando De León
Journal:  Neurol Sci       Date:  2017-07-25       Impact factor: 3.307

Review 5.  Different Prognostic Patterns in Epilepsies and Considerations About the Denotations of Atypical Patterns.

Authors:  Arife Çimen Atalar; Betül Baykan
Journal:  Noro Psikiyatr Ars       Date:  2022-01-31       Impact factor: 1.339

6.  The psychosocial impact of COVID-19 within the first six months of the pandemic on youth with epilepsy and their caregivers.

Authors:  Avani C Modi; Anup D Patel; Jack Stevens; Gigi Smith; Heather Huszti; Shanna M Guilfoyle; Constance A Mara; Matthew Schmidt; Janelle L Wagner
Journal:  Epilepsy Behav       Date:  2021-02-12       Impact factor: 2.937

Review 7.  Contrast-enhanced ultrasound of the pediatric brain.

Authors:  Misun Hwang; Carol E Barnewolt; Jörg Jüngert; Francesco Prada; Anush Sridharan; Ryne A Didier
Journal:  Pediatr Radiol       Date:  2021-02-18

8.  Sociodemographic factors associated with the first administration of anti-seizure medication in patients with focal epilepsy in Western China.

Authors:  Qiong Zhu; Yi Guo; Shuai Ma; Lili Yang; Zhonghua Lin; Hongbin Sun; Guangzong Li; Liang Yu
Journal:  BMC Neurol       Date:  2021-06-29       Impact factor: 2.474

9.  EpiNet as a way of involving more physicians and patients in epilepsy research: Validation study and accreditation process.

Authors:  Peter S Bergin; Ettore Beghi; Lynette G Sadleir; Alice Brockington; Manjari Tripathi; Mark P Richardson; Elisa Bianchi; Kavita Srivastava; Jayaganth Jayabal; Benjamin Legros; Michel Ossemann; Nicole McGrath; Alberto Verrotti; Hui Jan Tan; Simone Beretta; Richard Frith; Ivan Iniesta; Emma Whitham; Jithangi Wanigasinghe; Birinus Ezeala-Adikaibe; Pasquale Striano; Ian Rosemergy; Elizabeth B Walker; Maia Alkhidze; Ildefonso Rodriguez-Leyva; Jose Alfredo Ramírez González; Wendyl J D'Souza
Journal:  Epilepsia Open       Date:  2017-01-03

10.  A Proline Derivative-Enriched Fraction from Sideroxylon obtusifolium Protects the Hippocampus from Intracerebroventricular Pilocarpine-Induced Injury Associated with Status Epilepticus in Mice.

Authors:  Pedro Everson Alexandre de Aquino; Jéssica Rabelo Bezerra; Tyciane de Souza Nascimento; Juliete Tavares; Ítalo Rosal Lustosa; Adriano José Maia Chaves Filho; Melina Mottin; Danielle Macêdo Gaspar; Geanne Matos de Andrade; Kelly Rose Tavares Neves; Giuseppe Biagini; Edilberto Rocha Silveira; Glauce Socorro de Barros Viana
Journal:  Int J Mol Sci       Date:  2020-06-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.